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South Africa, with an estimated 5.7 million people living with HIV, 
has the largest burden of HIV disease globally.1 By 2009, an estimated 
2.9 million South Africans had died of AIDS, with an annual AIDS 
mortality of 374 000.2 The Free State (FS), one of 9 provinces in South 
Africa, with an estimated population of 2 792 000,2 has an AIDS 
prevalence rate of 18.5% among 15 - 49-year-olds, compared with the 
national figure of 16.9%.3
To combat the social disaster in high-burden countries, calls were 
made in 2003 to start the formidable task of getting antiretrovirals 
(ARVs) to people who needed them.4 By the end of 2008, the World 
Health Organization (WHO) estimated that over 4 million people had 
accessed ARVs in developing countries. In South Africa, specifically, 
700 500 people were reported to be accessing ARVs.5 UNAIDS has 
published estimates of the total need for ARVs in different regions, 
defined as the number of people accessing ARVs plus those who 
qualify for ARVs, i.e. either with stage 4 disease (AIDS) or a CD4 
count <200 cells/µl. Using this definition, an estimated 42% of people 
in developing countries who need ARVs are accessing them.5
In 2003, the South African National Department of Health (DOH) 
launched the national ARV roll-out with its Comprehensive Plan for 
the Care, Management and Treatment of HIV and AIDS (Operational 
Plan). Its aim was to achieve universal ARV access (an estimated 
1.4 million people in need of ARVs at that stage) within 5 years.6 
Although the OP’s stated aim was to provide comprehensive HIV 
care in an integrated fashion, the roll-out was delivered as a vertical 
programme with dedicated funding, staffing and administration, and 
closely controlled national accreditation of ARV sites.6
International debate continues on the merits of horizontal versus 
vertical programmes for delivering HIV care in developing countries. 
The advantage of vertical (stand-alone) programmes is their ability 
to deliver rapid roll-out of the type of complex health intervention 
needed to tackle HIV.7 However, it is thought that such vertical 
programmes will not be able to achieve universal access and that they 
need to be broadened using the new so-called diagonal approach.8 
By 2006 it was clear that universal access to ARVs in South Africa 
would take more than 5 years to achieve. Less than 30% of those in 
need were accessing ARVs.5 In 2007, the DOH published its National 
Strategic Plan (NSP) with detailed annual goals, aiming to achieve 
access to ARVs for 80% of the people who would need them by 
2011,9 and defining the need for ARVs as the number of new AIDS 
patients, estimated at about 520 000 annually, from 2007 to 2011.3 In 
contrast with the WHO definition of need for ARVs, the former was 
an annual figure against which one can measure the number of new 
patients accessing ARVs each year, but it does not include estimates 
of people with a CD4 count below 200 cells/µl and therefore probably 
underestimates need.
In the FS, the ARV roll-out began in mid-2004 as a vertical 
programme with plans to establish ARV sites in each of its 20 local 
areas.10 Two types of ARV sites were established. Treatment sites 
were led by doctors, where patients were referred for initiation and 
monitoring of ARVs. These were linked to nurse-led assessment sites Corresponding author: Kerry E Uebel (uebelke@fshealth.gov.za)
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Objective. To study the progress and challenges with regard to 
universal antiretroviral (ARV) access in Free State Province, South 
Africa.
Methods. Data from the first 4 years of the public sector ARV 
roll-out and selected health system indicators were used. Data 
were collected from the public sector ARV database in Free 
State Province for new patients on ARVs, average waiting times 
and median CD4 counts at the start of treatment. Information 
on staff training, vacancy rates and funding allocations for the 
ARV roll-out was obtained from official government reports. 
Projections were made of expected new ARV enrolments for 
2008 and 2009 and compared with goals set by the National 
Strategic Plan (NSP) to achieve universal access to ARVs by 2011. 
Results. New ARV enrolments increased annually to 25% of the 
estimated need by the end of 2007. Average waiting times to 
enrolment decreased from 5.82 months to 3.24 months. Median 
CD4 counts at enrolment increased from 89 to 124 cells/µl. There 
is a staff vacancy rate of 38% in the ARV programme and an 
inadequate increase in budget allocations.
Conclusion. The current vertical model of ARV therapy delivery 
is unlikely to raise the number of new enrolments sufficiently to 
achieve the goals of universal access by 2011 as envisaged by the 
NSP. The Free State is implementing a project (STRETCH trial) to 
broaden the ARV roll-out in an attempt to increase access to ARVs.
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in primary health care (PHC) facilities, where patients would be 
screened and prepared for ARVs and be able to collect medication. 
This model was adapted particularly for small-town sites with the 
accreditation of combined sites, i.e. a nurse-led assessment site with 
doctors visiting regularly. Reviews of the FS roll-out noted that 
the vertically run ARV programme drained staff from other PHC 
facilities and that problems were experienced with integration of 
ARV care into PHC services.11
Our study has lessons for achieving universal access to ARVs in 
high-burden countries. Our objective was to attempt to answer two 
questions: (i) what is the progress towards universal ARV access 
in the FS in the first 4 years of the roll-out; and (ii) how do the 
challenges in the FS inform the debate on the merits of vertical versus 
horizontal delivery systems in achieving universal ARV access in 
high-burden countries?
Methods
Study design and data collection
A retrospective, observational study was conducted using data 
from a variety of sources. Information on the number of ARV sites 
established in the FS from May 2004 until June 2008, expenditure, 
and staff vacancy rates for the ARV programme was obtained 
from the province’s Directorate: Comprehensive HIV and AIDS 
Management. Information on conditional grant allocations was 
obtained from the National Treasury website.12 Data on patients 
initiated on ARVs were obtained from the FS ARV database. Routine 
clinical data from all public sector ARV sites in the FS (with the 
exception of 3 small-town sites not yet online) were entered on an 
electronic record system (Meditech) by clinic-based data capturers. 
The data were incorporated in a data warehouse and used for 
monitoring and evaluation. This routinely collected dataset was 
supplemented by linkage to the National Health Laboratory Service 
(NHLS) database. Information on the estimated annual number of 
new AIDS patients in the FS was retrieved from the Actuarial Society 
of Southern Africa’s 2003 model of demographic indicators for the 
HIV epidemic.13
Permission to conduct this study was granted by the Head of the 
FS Department of Health. The Ethics Committee of the Faculty 
of Health Sciences, University of the Free State, approved the 
protocol.
Staff training
The FS Department of Health runs a regular 2-week ARV training 
course for medical, nursing and ancillary staff. Information 
on staff training was obtained from the province’s Directorate: 
Human Resource Management, and from district managers. It has 
also implemented on-site training in integrated management of 
respiratory illnesses, tuberculosis (TB), HIV (including ARVs) and 
sexually transmitted infections (STIs) in adults, using the PALSA 
PLUS guidelines.14
Statistical analysis
The monthly new ARV enrolments from 2004 to 2007 were plotted 
and an extrapolation of a linear trend line was fitted to the data to 
project expected increases for 2008 and 2009 using statistical packages 
available in Microsoft Excel. Median waiting times for ARV initiation 
were calculated using Kaplan-Meier estimates. Waiting time was 
defined as time between first CD4 count <200 cells/µl and initiation 
of ARVs. Patients who died before the start of treatment or who were 
not observed to start ARVs were censored in these analyses. Median 
CD4 counts at commencement of ARVs were calculated over 3-month 
periods. The significance of a trend over time in enrolment CD4 counts 
was checked using an extension of the Wilcoxon rank sum test. Survival 
analyses and tests for trend were done using Stata version 10.1.
Results
The number of all types of sites increased steadily from 20 sites in 6 
local areas by the end of 2004, to 56 sites by August 2008, with at least 
1 site in each of the 20 local areas. There were 11 treatment sites, 27 
assessment sites and 18 combined sites.
The number of new patients (adults and children) 
commencing ARVs each month increased steadily, peaking at 
1 045 in October 2007 (Fig. 1). Comparing the annual number of 
patients starting ARVs with the estimated number of new AIDS 
patients for 2004 - 2007,13 the percentage coverage increased from 2% 
in 2004 to 25% in 2007 (Table I). Patients were distributed unevenly 
across the 56 sites, with 7 urban sites each having initiated treatment 
on more than 1 000 patients.
Should the expansion of the ARV roll-out continue as in the period 
2004 - 2007, monthly new ARV enrolments for 2008 and 2009 could 
be expected to have increased as in the trend line in Fig. 1. According 
to this projection, about 11 500 patients would have started ARVs in 
2008 and about 14 300 in 2009, representing about 31% and 39% of 
estimated new AIDS patients, respectively.13 These percentages would 
fall short of the goal of the NSP9 to increase enrolment of new patients 
on ARVs to 35% of need in 2008 and 55% in 2009 (Table II). If, 
however, NSP goals were achieved in the FS, the cumulative number 
of patients on treatment at ARV sites would more than double to 
reach approximately 44 267 (Table II).
The median waiting times from eligibility (CD4 count <200 
cells/µl) to starting ARVs decreased from 5.82 months in 2004 to 
3.24 months in 2007 (Table III). The analysis of waiting times was 
 11
 
 
 
NB: The time axis, x, uses a computer generated date code in the linear regression formula. 
R2 is the coefficient of determination showing relationship between ARV enrolments and time. 
 
Fig. 1. Monthly new enrolments (2004) plotted against need and goals as envisaged in 
the National Strategic Plan 2008 and 2009. 
 
Fig. 1. Monthly new enrolments (2004) plotted against need and goals as 
envisaged in the National Strategic Plan 2008 and 2009.
Table I. Annual enrolments on ARVs compared with estimated 
new AIDS patients in the Free State 2004 - 2007
     Total
     enrolled on 
     ARVs (% 
Year  New AIDS patients  of need)
2004            29 104  642 (2.2)
2005            32 124  3 091 (9.6)
2006            34 431  5 420 (15.7)
2007            36 012  9 157 (25.4)
Total            131 671  18 310
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repeated using cumulative incidence functions to account for the 
competing risk of patients dying before accessing treatment. This 
made no difference to the trend of median waiting times decreasing 
over time. Pre-ARV CD4 cell counts were available in the dataset for 
75% of the 17 847 patients who started ARVs by December 2007. 
Many CD4 results were not entered onto the database, particularly 
in 2006 and 2007, as workload increased and not all missing results 
could be matched from the NHLS database.
The median baseline CD4 cell counts at commencement 
of ARVs rose from 89 cells/µl (interquartile range (IQR) 
49 - 156) in the second quarter of 2004 to 124 cells/µl (IQR 55 - 84) in 
the last quarter of 2007 (Fig. 2). There is strong evidence of a positive 
trend over time (z=7.71 Prob >|z|=0).
Human resources and training. By June 2008, 534 posts had 
been created in the ARV programme, although 207 (38.8%) were 
vacant. Of the professional posts, 39% nurses’, 50% doctors’ and 59% 
pharmacists’ posts were vacant.
Training of staff in the management of HIV including ARVs was 
not restricted to staff from the ARV programme. From May 2004 
until August 2008, 2 540 members of staff, including 251 doctors 
and 1 130 professional nurses, had completed the 2-week ARV 
training course. At least 1 professional nurse from every PHC clinic 
in the province had been trained. By August 2008, staff in 139 of 
the approximately 240 PHC clinics had been trained in managing 
patients using the PALSA PLUS guidelines.
Funding for the ARV roll-out is provided by the DOH, with 
an annual allocation to the provinces of a conditional grant for 
comprehensive HIV and AIDS management. Amounts allocated 
to the FS have improved annually, with more than 40% increases 
over the first 2 years, a 24% increase in 2007/2008 for the 2008/2009 
financial year, and a 20% increase from 2008/2009 to 2009/2010. Of 
the R153 646 000 allocated in the 2007/2008 conditional grant to the 
FS, 35% was spent on drugs and laboratory tests, and 39% on staff 
remuneration for full-time and lay workers in the ARV sites. The rest 
was spent on training, prevention programmes, infrastructure, step-
down care and programme management.
Discussion
The public sector ARV programme in the FS achieved steadily rising 
numbers of monthly new enrolments on ARVs and decreasing 
waiting times for those eligible for ARVs. CD4 counts were higher at 
commencement of ARVs, and ARV services were provided in all its 
20 local areas. These findings suggest that the programme is making 
inroads into the shortfall, and people are accessing ARVs more 
readily. Published figures show good outcomes of patients receiving 
ARVs in the public sector in the FS, with a 7% mortality rate and an 
82% viral load suppression rate at 1 year.15
Table II. Goals for new enrolments on ARVs for the Free State as envisaged in the National Strategic Plan (NSP)
      Goals for new           Estimated 
    Monthly new enrolments            Monthly new        cumulative 
             New AIDS  enrolments to according to            enrolments to        numbers on 
Year             patients  meet need  NSP (%)            meet NSP goals        ARVs*
2008             36 861  3 070  12 901 (35)            1 075        28 360
2009             37 059  3 090  20 382 (55)            1 700        44 267
2010             36 737  3 070  25 716 (70)            2 140        63 912
2011             36 042  3 000  28 834 (80)            2 400        85 225
*Cumulative numbers on ARVs assume a 15% dropout of new patients and a 5% dropout of previous patients owing to deaths and defaulting on ARVs.
Fig. 2. Plot of median CD4 cell counts at initiation of ARVs* and their IQRs 
at each quarter, N=5 918. (*Based on 5 918 patients with a CD4 result in the 
period 6 weeks before - 4 weeks after commencement of ARVs.)
 
 
 
Fig. 2. Plot of median CD4 cell counts at initiation of ARVs* and their IQRs at each quarter, 
N=5 918. (*Based on 5 918 pati nts with a CD4 result in the period 6 weeks before - 4 weeks 
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Table III. Waiting time from eligibility to treatment for each calendar year and health district (N=22 496)*
       Year of enrolment
District             2004            2005       2006   2007
   N MWT                   N MWT                N           MWT             N       MWT
Fezile Dabi  363 6.84                  734 3.04               883         3.44              769      3.04
Xhariep   422 11.27                  331 6.21               591         3.80              539      2.78
Motheo   1 624 6.02                  1 599 7.90               1 126      5.02              2 428    3.83
Lejweleputswa  914 4.83                  1 146 3.50               1 416      3.07              1 331    2.84
Thabo Mofutsanyane  676 4.86                  1 544 6.55               2 210      6.28              1 850    2.74
Total   3 999 5.82                  5 354 5.75               6 226      4.36              6 917    3.24
*N represents patients who commenced ARVs and had a pre-ARV CD4 count available. The number of patients with missing CD4 results in the database increased in 2006 and 2007, probably ow-
ing to increased workload at the sites. MWT = median waiting time (months).
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A strength of this study is the availability and completeness of 
data for patients before and during ARV initiation, supplemented 
by linkages with the NHLS database. A weakness as a retrospective 
study is that, because of an increasing data entry backlog, no accurate 
figures are available on patient retention in the ARV programme. 
Furthermore, these findings do not include data for patients on ARVs 
outside the public sector in the FS.
However, assuming that most people who need ARVs in 
the FS will only have access to public facilities, the percentage 
that accessed ARVs is small and the FS has a long way to go 
towards universal ARV coverage. From 2004 to 2007, only 
18 310 people were initiated on ARVs in the public sector (Table I), 
whereas an estimated 131 671 developed AIDS in those 4 years.13 
Even in 2007, ARV initiations reached only 25% of the estimated 
need. Presumably, many of those who did not start ARVs have died. 
In the FS public sector, the mortality rate of people with CD4 counts 
<350 cells/µl is 53% at 1 year, most of whom (87%) did not start 
ARVs.15
Projections of patients starting ARVs in 2008 and 2009, based on 
the performance of the programme in the first 4 years, suggest that by 
2009 only 39% of the newly ill patients with AIDS would access ARVs 
in the public sector. This figure is below the NSP’s goal of 55% of 
patients who need ARVs being able to access them by 2009.9 If the FS 
manages to achieve NSP goals, the cumulative number of people on 
ARVs would increase by about 150%. The 7 large urban sites handling 
chronic ARV care for more than 1 000 patients by the end of 2007 
would increase patient load to more than 2 500. Subsequently, this 
increasing load of chronic care would soon see clinics exceed their 
capacity, a problem noted by other ARV sites in South Africa.16
Considering the shortage of human and financial resources, even 
modest projected increases for 2008 and 2009 may not be achievable, 
especially if the ARV roll-out is continued as a vertical programme. Of 
the 534 new posts created in the ARV programme, 38.8% were vacant 
by June 2008. This may be related to findings of a high level of burnout 
and compassion fatigue among ARV and PHC nurses in the FS.17
Funding of comprehensive HIV care in the FS increased by only 
24% in the 2008/2009 budget, and by 20% in the 2009/2010 budget, 
whereas expected costs for drugs and laboratory tests (costs directly 
related to the number of people on ARVs and already taking up 
35% of the budget) would have increased by 150% if there were over 
44 000 people on ARVs by the end of 2009. Although the public 
sector ARV programme in the FS is increasing the access to ARVs 
for people who need them, human and financial resources appear 
insufficient to achieve universal coverage, particularly if the vertical 
approach is continued.
Several models of broadening an initial vertical approach to 
achieve universal ARV access include: (i) down-referral, where ARV 
sites refer stable patients to obtain their continuing ARV supply at 
PHC clinics.18 This approach was mostly used as an afterthought to 
solve the problem of a saturated vertical service, but others see it as 
a gateway to integrate the provision of ARVs into PHC services; (ii) 
task shifting, a strategy supported by WHO,19 the essence of which 
is to equip and utilise lower cadres of health care workers to deliver 
comprehensive HIV care as a strategy to overcome shortages of highly 
skilled health care workers; and (iii) integration of HIV and ARV care 
into PHC services, a strategy implemented by 3 rural subdistricts in 
South Africa that have almost reached universal access.20
The FS DOH decided to broaden the programme by using a 
combination of task shifting (equipping nurses to initiate and repeat 
ARV prescriptions for uncomplicated patients) and integration 
of comprehensive HIV care into PHC services. The intervention 
commenced in early 2008 and is being implemented and evaluated 
as a pragmatic randomised controlled trial (STRETCH trial) in 31 
of the current ARV sites, and is due to be completed in June 2010.21 
The South African National DOH recently announced its accelerated 
AIDS plan with the aim of increasing access to antiretroviral therapy 
(ART).22 Task shifting and integration of ART into primary care 
services are central components of this plan. The experience of 
the STRETCH trial should provide important lessons in how to 
implement such a diagonal approach to expanding ART care and 
particularly how to equip and support nurses in primary care services 
to provide ART care.23
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